It is a multinational study investigating the safety and efficacy of biphasic insulin aspart 30/70 (BIAsp 30) in the routine management of patients with Type 2 diabetes mellitus. Five published ...

A study in the journal Diabetes Technology & Therapeutics (DTT) concludes that inhaled technosphere insulin (TI-Afrezza) ...

A new study in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT) concluded that inhaled technosphere insulin ...

The US Food and Drug Administration approved the first-ever rapid-acting insulin for reducing blood sugar levels. It calls the new drug “Merilog,” a biosimilar to the widely-used insulin product ...

Under the terms of the agreement, Biocon Biologics will supply insulin aspart drug substance to Civica, who will use the drug substance to produce insulin aspart drug product, a rapid-acting insulin ...

This partnership is in addition to Biocon Biologics’ own Insulin Aspart drug product, which is currently under review by the US Food and Drug Administration (FDA).

Find all the commercial and brand names of generic drug called Insulin Aspart. This is an invaluable reference resource for healthcare professionals, patients, caregivers and anyone in need of ...

Biocon Biologics has partnered with Civica to improve access to and affordability of insulin aspart in the U.S. Biocon will supply the insulin, while Civica will manufacture and commercialize it, ...

Enrollment of large, culturally diverse study populations allowed the examination ... their quota of patients was reached. Biphasic insulin aspart 30/70 was administered once, twice or three ...

Under the terms of the agreement, Biocon Biologics will supply Insulin Aspart drug substance to Civica, Inc., who will use the drug substance to produce Insulin Aspart drug product, a rapid-acting ...